NEOS Investment Management LLC Buys 11,704 Shares of Agilent Technologies, Inc. $A

NEOS Investment Management LLC boosted its stake in Agilent Technologies, Inc. (NYSE:A) by 46.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 36,857 shares of the medical research company’s stock after purchasing an additional 11,704 shares during the quarter. NEOS Investment Management LLC’s holdings in Agilent Technologies were worth $4,731,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in A. Capital A Wealth Management LLC boosted its holdings in Agilent Technologies by 10,600.0% in the second quarter. Capital A Wealth Management LLC now owns 214 shares of the medical research company’s stock worth $25,000 after acquiring an additional 212 shares in the last quarter. Davis Capital Management acquired a new position in shares of Agilent Technologies during the third quarter worth approximately $28,000. Physician Wealth Advisors Inc. lifted its holdings in shares of Agilent Technologies by 490.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 236 shares of the medical research company’s stock worth $30,000 after purchasing an additional 196 shares in the last quarter. State of Wyoming acquired a new stake in Agilent Technologies in the 2nd quarter valued at $35,000. Finally, SJS Investment Consulting Inc. increased its stake in Agilent Technologies by 2,836.4% during the 3rd quarter. SJS Investment Consulting Inc. now owns 323 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 312 shares in the last quarter.

Insiders Place Their Bets

In other Agilent Technologies news, VP Rodney Gonsalves sold 3,000 shares of the firm’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $154.99, for a total value of $464,970.00. Following the completion of the sale, the vice president directly owned 31,846 shares of the company’s stock, valued at $4,935,811.54. This trade represents a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. UBS Group upped their target price on shares of Agilent Technologies from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Bank of America increased their price objective on Agilent Technologies from $150.00 to $165.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 25th. JPMorgan Chase & Co. raised their target price on Agilent Technologies from $165.00 to $180.00 and gave the company an “overweight” rating in a report on Tuesday, November 25th. Citigroup upped their price target on Agilent Technologies from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Finally, Morgan Stanley began coverage on Agilent Technologies in a research note on Tuesday, December 2nd. They set an “overweight” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $164.50.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $126.89 on Thursday. The business’s fifty day simple moving average is $136.84 and its 200 day simple moving average is $135.62. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 0.45. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $160.27. The firm has a market capitalization of $35.89 billion, a P/E ratio of 27.77, a price-to-earnings-growth ratio of 3.60 and a beta of 1.30.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.01. The company had revenue of $1.86 billion during the quarter, compared to analyst estimates of $1.83 billion. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.46 earnings per share. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. As a group, analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 22nd. Investors of record on Tuesday, March 31st will be paid a $0.255 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $1.02 annualized dividend and a yield of 0.8%. Agilent Technologies’s dividend payout ratio is presently 22.32%.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.